A therapeutic potential of soluble decoy receptor 3 in sepsis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$112,572.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
1R43GM076828-01
Award Id:
79689
Agency Tracking Number:
GM076828
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
BIOPOWERTECH, 4734 BLUEGRASS PKY, TUSCALOOSA, AL, 35406
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SUNGHEE KIM
(205) 345-2512
sunghee_kim_bpt@yahoo.com
Business Contact:
STAVROS BELBAS
(205) 345-2512
S_BELBAS_BPT@YAHOO.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Sepsis a serious life-threatening condition resulting from a harmful inflammatory reaction of the body due to bacterial infection. The mortality rate of sepsis remains high in intensive care units around the world but therapeutic interventions have been largely unsuccessful. Clearly, there is a great need for inventing efficacious therapeutic drugs to treat patients with sepsis associated illnesses. Increasing evidence indicates that aberrant apoptosis (programmed cell death) plays a key role in sepsis-related death but currently no drugs to prevent apoptosis in sepsis are available for clinical use. A soluble receptor protein has been demonstrated for its survival effects in animal lethality induced by apoptosis. Moreover, the level of this protein was significantly elevated in human cells in response to bacterial antigens and in sera of patients with bacterial infections thus indicating that the protein might play an important role in the pathogenesis of bacterial infection and sepsis. Therefore, we propose to accomplish two goals in this Phase I SBIR study. First, we propose to develop a high quality recombinant receptor protein so that the protein can be safe and effective for clinical use. Second, to evaluate the future therapeutic potential of the protein to treat septic patients, we propose to test whether the protein provides a survival advantage in an animal model of sepsis. Undoubtedly, our phase I SBIR studies will enhance our ability to advance to future SBIR studies designed to further evaluate the efficacy of the protein in clinical settings. If this soluble receptor protein can be effective for treating patients with sepsis, this will increase the success rate of therapy thus reducing the burden of medical care costs, as well as enhancing the quality of the patients' life

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government